Michael Hall

1.7k total citations
21 papers, 1.0k citations indexed

About

Michael Hall is a scholar working on Molecular Biology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, Michael Hall has authored 21 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 8 papers in Radiology, Nuclear Medicine and Imaging and 5 papers in Immunology. Recurrent topics in Michael Hall's work include Monoclonal and Polyclonal Antibodies Research (7 papers), Protein purification and stability (6 papers) and Biosimilars and Bioanalytical Methods (5 papers). Michael Hall is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (7 papers), Protein purification and stability (6 papers) and Biosimilars and Bioanalytical Methods (5 papers). Michael Hall collaborates with scholars based in United States. Michael Hall's co-authors include Jean W. Lee, Yung‐Mae Yao, Chris Spahr, W. H. Wright, David E. Cooper, Johannes Hampl, Naheed A. Mufti, David MacQueen, Hossein Salimi-Moosavi and Qingchun Zhang and has published in prestigious journals such as Analytical Chemistry, Analytical Biochemistry and Endocrinology.

In The Last Decade

Michael Hall

20 papers receiving 997 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Hall United States 14 681 279 202 168 162 21 1.0k
Scott L. Klakamp United States 16 580 0.9× 326 1.2× 180 0.9× 134 0.8× 57 0.4× 26 881
Petri Saviranta Finland 19 877 1.3× 351 1.3× 72 0.4× 230 1.4× 95 0.6× 38 1.1k
Yuwei Tian China 20 608 0.9× 163 0.6× 119 0.6× 58 0.3× 312 1.9× 37 931
Guinevere S. M. Lageveen‐Kammeijer Netherlands 19 1.0k 1.5× 263 0.9× 294 1.5× 106 0.6× 292 1.8× 40 1.3k
Reyna J. Simon United States 13 1.9k 2.7× 401 1.4× 154 0.8× 72 0.4× 164 1.0× 20 2.3k
Benjamin T. Walters United States 17 785 1.2× 202 0.7× 92 0.5× 52 0.3× 345 2.1× 28 1.1k
Thomas J. Tolbert United States 21 1.1k 1.6× 429 1.5× 127 0.6× 40 0.2× 132 0.8× 48 1.3k
William R. Alley United States 18 1.2k 1.8× 267 1.0× 190 0.9× 165 1.0× 510 3.1× 23 1.4k
Judith Senior United Kingdom 12 842 1.2× 147 0.5× 135 0.7× 165 1.0× 56 0.3× 16 1.3k
Jason K. Cheung United States 21 1.0k 1.5× 659 2.4× 122 0.6× 204 1.2× 106 0.7× 29 1.2k

Countries citing papers authored by Michael Hall

Since Specialization
Citations

This map shows the geographic impact of Michael Hall's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Hall with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Hall more than expected).

Fields of papers citing papers by Michael Hall

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Hall. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Hall. The network helps show where Michael Hall may publish in the future.

Co-authorship network of co-authors of Michael Hall

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Hall. A scholar is included among the top collaborators of Michael Hall based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Hall. Michael Hall is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lee, Catherine, Ziyue Karen Jiang, Simon Planken, et al.. (2023). Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer. Molecular Cancer Therapeutics. 22(7). 891–900.
2.
3.
Stanislaus, Shanaka, Randy Hecht, Junming Yie, et al.. (2017). A Novel Fc-FGF21 With Improved Resistance to Proteolysis, Increased Affinity Toward β-Klotho, and Enhanced Efficacy in Mice and Cynomolgus Monkeys. Endocrinology. 158(5). 1314–1327. 81 indexed citations
4.
Zhang, Qingchun, et al.. (2016). Characterization of the co‐elution of host cell proteins with monoclonal antibodies during protein A purification. Biotechnology Progress. 32(3). 708–717. 57 indexed citations
5.
Jawa, Vibha, Marisa K. Joubert, Qingchun Zhang, et al.. (2016). Evaluating Immunogenicity Risk Due to Host Cell Protein Impurities in Antibody-Based Biotherapeutics. The AAPS Journal. 18(6). 1439–1452. 71 indexed citations
6.
Winkler, Michael, Stephen Hobbs, Richard Charnigo, et al.. (2015). Identification of Coronary Artery Calcification and Diagnosis of Coronary Artery Disease by Abdominal CT. Academic Radiology. 22(6). 704–707. 6 indexed citations
7.
Hall, Michael. (2014). Biotransformation and In Vivo Stability of Protein Biotherapeutics: Impact on Candidate Selection and Pharmacokinetic Profiling. Drug Metabolism and Disposition. 42(11). 1873–1880. 43 indexed citations
8.
Argintar, Evan, et al.. (2013). Recommendations for Driving After Right Knee Arthroscopy. Orthopedics. 36(5). 659–665. 10 indexed citations
9.
Hager, Todd, Chris Spahr, Jing Xu, Hossein Salimi-Moosavi, & Michael Hall. (2013). Differential Enzyme-Linked Immunosorbent Assay and Ligand-Binding Mass Spectrometry for Analysis of Biotransformation of Protein Therapeutics: Application to Various FGF21 Modalities. Analytical Chemistry. 85(5). 2731–2738. 51 indexed citations
10.
Hall, Michael, James Ward, & Dennis A. Cardone. (2013). Platelet rich placebo? Evidence for platelet rich plasma in the treatment of tendinopathy and augmentation of tendon repair.. PubMed. 71(1). 54–9. 13 indexed citations
11.
Li, Hongyan, Linh T. Tran, Michael Hall, et al.. (2012). General LC-MS/MS Method Approach to Quantify Therapeutic Monoclonal Antibodies Using a Common Whole Antibody Internal Standard with Application to Preclinical Studies. Analytical Chemistry. 84(3). 1267–1273. 151 indexed citations
12.
13.
Lee, Jean W. & Michael Hall. (2008). Method validation of protein biomarkers in support of drug development or clinical diagnosis/prognosis☆. Journal of Chromatography B. 877(13). 1259–1271. 74 indexed citations
14.
Hall, Michael, et al.. (2005). Stable isotope methods for high-precision proteomics. Drug Discovery Today. 10(5). 353–363. 58 indexed citations
15.
Hall, Michael, et al.. (2004). Isotope-differentiated binding energy shift tags (IDBEST™) for improved targeted biomarker discovery and validation. Expert Review of Proteomics. 1(4). 421–431. 23 indexed citations
16.
Hampl, Johannes, Michael Hall, Naheed A. Mufti, et al.. (2001). Upconverting Phosphor Reporters in Immunochromatographic Assays. Analytical Biochemistry. 288(2). 176–187. 231 indexed citations
17.
Hall, Michael, et al.. (1999). High Sensitivity Immunoassays Using Particulate Fluorescent Labels. Analytical Biochemistry. 272(2). 165–170. 55 indexed citations
18.
Hall, Michael, et al.. (1998). Interactions of a vesicular stomatitis virus G protein fragment with phosphatidylserine: NMR and fluorescence studies. Biochimica et Biophysica Acta (BBA) - Biomembranes. 1415(1). 101–113. 19 indexed citations
19.
Faris, Gregory W., W. H. Wright, Michael Hall, et al.. (1998). Upconverting Phosphors as Reporters for Immunoassay. 61. BTuB4–BTuB4. 1 indexed citations
20.
Hall, Michael & Wray H. Huestis. (1994). Phosphatidylserine headgroup diastereomers translocate equivalently across human erythrocyte membranes. Biochimica et Biophysica Acta (BBA) - Biomembranes. 1190(2). 243–247. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Scott L. Klakamp Breakdown of academic impact, for papers by Petri Saviranta Breakdown of academic impact, for papers by Yuwei Tian Breakdown of academic impact, for papers by Guinevere S. M. Lageveen‐Kammeijer Breakdown of academic impact, for papers by Reyna J. Simon Breakdown of academic impact, for papers by Benjamin T. Walters Breakdown of academic impact, for papers by Thomas J. Tolbert Breakdown of academic impact, for papers by William R. Alley Breakdown of academic impact, for papers by Judith Senior Breakdown of academic impact, for papers by Jason K. Cheung
Rankless by CCL
2026